ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS

Registry ID

EUCTR2013-003826-10

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

IRCCS- Mario Negri Institute

Start date

2014-01-14

Completion date

2017-12-19

Last update

2026-08-16

Conditions

• Membranoproliferative glomerulonephritis

Summary

To evaluate whether Eculizumab therapy may reduce 24 hour proteinuria, considered as a continuous variable, at 6 months (week-24) and 12 months (week-48) compared to baseline

Locations

• , , Italy

View on source registry